Can-Fite BioPharma Ltd.

CANF chart

Can-Fite BioPharma Ltd. news

• Can-Fite BioPharma Namodenoson Pancreatic Cancer Results Presented at ESMO

  Kalkine · Oct 26, 9:24 AM EDT

• Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026

  Yahoo Finance · Oct 26, 7:00 AM EDT

• No serious treatment-related side effects were reported in Can-Fite's pancreatic cancer study.

  Stock Titan · Oct 26, 7:00 AM EDT

• Can-Fite BioPharma Ltd. Estimates – TASE:CANF

  TradingView · Oct 24, 12:33 AM EDT

• CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Price & Overview

  ChartMill · Oct 23, 3:00 AM EDT

• Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

  Yahoo Finance · Sep 9, 7:00 AM EDT

• Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

  Yahoo Finance · Sep 8, 8:20 AM EDT

• Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

  Yahoo Finance · Sep 2, 11:48 AM EDT

• Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

  Yahoo Finance · Sep 2, 9:02 AM EDT

• Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

  Yahoo Finance · Sep 2, 7:00 AM EDT

• Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

  Yahoo Finance · Aug 17, 7:00 AM EDT

• Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

  Yahoo Finance · Aug 12, 7:00 AM EDT

Can-Fite BioPharma Ltd. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-10-26
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-09
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-08
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-03
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-02
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-02
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-17
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-12
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-03
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-20
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-14
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-06

About Can-Fite BioPharma Ltd.

Ticker

CANF (NYSE)

Industry

Pharmaceutical Preparations

Headquarters

Ramat Gan, Israel

Incorporated in

Israel

Fiscal year end

December 31

SEC CIK

1536196

Frequently asked questions